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A B S T R A C T
Stroke represents the third leading cause of death in the USA and the most common 
and disabling neurological disorder in the elderly population. A carotid stenosis is re-
sponsible for about 30% of the cases. Medical therapy with antithrombotic agents and 
statins has a role in reducing cardiovascular risk, but randomized trials have shown 
that carotid endarterectomy (CEA) is superior to medical therapy alone and is consid-
ered the gold standard treatment of a carotid stenosis. However, surgery is not without 
complications; the stroke and death rate at 30 days in these trials ranged from 5.8% 
to 7.5% in the symptomatic patients and from 2.3% to 4.3% in asymptomatic patients. 
In higher risk patients, like those with severe coronary artery disease, morbidity and 
mortality has been reported in up to 18% of patients.
Carotid angioplasty and stenting (CAS) has been proposed as an alternative to sur-
gery, and two initial randomized studies comparing CAS and CEA showed compa-
rable results. However, after these results, numerous studies, both European and 
American studies, have been published with very different outcomes. Among them 
the most important is the American study, CREST, which demonstrated that CAS 
is not inferior to CEA and can now be proposed to the majority of patients suffering 
from a carotid stenosis. But in contrast to many other endovascular interventions, 
CAS represents a more challenging procedure requiring complex catheter-based skills 
and an extensive learning curve that explains the poor results of CAS in some pub-
lished series and particularly in Europeans studies.
In conclusion, after the CREST study and recent published data, CAS and CEA can 
be deemed equivalent for the treatment of a carotid stenosis. However, these two 
treatments may have some contraindications and limitations. We need appropriate 
patient and lesion selection, proper technique, embolic protection devices, and most 
importantly experienced operators. Indications for asymptomatic patients have to be 
discussed considering the benefit of optimal medical therapy.
I n T R o d u C T I o n
Stroke represents the third leading cause of death in the US and the most com-
mon and disabling neurological disorder in the elderly population.1 A carotid stenosis 
is responsible for about 30% of these cases. The majority (>75%) of stroke patients 
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were asymptomatic before their stroke. Medical therapy (e.g. 
antiplatelets and lipid lowering agents) have a continuing 
role in reducing cardiovascular risk, but randomized trials2-7 
have shown that carotid endarterectomy (CEA) is superior to 
medical therapy alone and have demonstrated the efficiency 
of CEA in reducing the risk of stroke and death in sympto-
matic and asymptomatic patients. Based on these trials, CEA 
was considered as the gold standard treatment of a carotid 
stenosis. However, this operation is not without drawbacks 
and risks in high and low risks patients.8 The stroke and death 
rate at 30 days in these trials ranged from 5.8% to 7.5% in the 
symptomatic patients and from 2.3% to 4.3% in asymptomatic 
patients. In higher risk patients, like those with severe coronary 
artery disease, morbidity and mortality has been reported in 
up to 18% of patients.
Carotid angioplasty and stenting (CAS) has been proposed 
as an alternative to surgery, and two randomized studies 
comparing CAS and CEA had shown comparable results 
even without embolic protection devices (EPD).9,10 However, 
after these results, numerous studies have been published with 
very different outcomes; among them several device approval 
trials11 with results of CAS at least not inferior to surgery, and 
several European and American studies. Among the European 
studies, three stand out: the Endarterectomy Versus Angio-
plasty in patients with symptomatic severe carotid stenosis 
(EVA-3S),12 the Stent-Protected Angioplasty versus Carotid 
Endarterectomy in symptomatic patients (SPACE Study),13 
and the International Carotid Stenting Study (ICSS).14 Only 
the SPACE study has shown similar results between CAS and 
CEA. Among the American studies, the most recent and the 
most important one is the Carotid Revascularization Endar-
terectomy vs Stenting trial (CREST Study),15 a randomized 
controlled trial which demonstrated that CAS is not inferior 
to CEA. In contrast to many endovascular interventions, CAS 
represents a more challenging procedure requiring complex 
catheter-based skills and an extensive learning curve that ex-
plains the poor results of CAS in some published series and 
particularly in European studies.
In the present review, we would like to analyze these stud-
ies, and try to determine if the CREST Study has changed 
the current clinical practice in favor of CAS procedures at a 
time when the enthusiasm for endoluminal repair has been 
dampened by some studies and in particular European studies. 
R E g I S T R I E S  –  R A n d o m I z E d  
S T u d I E S :  R E S u L T S
1 .  d E v I C E  A P P R o vA L  T R I A L S 1 1
Since 2002, 11 device-approval trials in high-risk patients 
were reported showing rapidly improving outcomes as dem-
onstrated in Figure 1. The SAPPHIRE study randomized 
317 high-risk patients to either CEA or CAS with an EPD 
(Angioguard, Cordis, Bridgewater, NJ, USA). The 30-day 
composite index of stroke/death/myocardial infarction (MI) 
rate was 4.8% for CAS and 9.8% for CEA (P = 0.09) and 
results at 1 year favored CAS, 12.2% vs 20.1% (P = 0.048). 
Ten other pivotal registries reported data at least comparable 
to CEA (Table 1).11
2 .  E u R o P E A n  S T u d I E S :  E vA - 3 S ,  S PA C E ,  I C S S 
S T u d I E S 1 2 - 1 4
The 30-day outcomes (stroke/death/MI rate) are sum-
marized in Table 2.
Only the SPACE study showed similar results between the 
two treatments. However, these studies have a lot of limita-
tions: a high failure rate of CAS of 3 to 5% (EVA-3S, SPACE) 
which is usually not seen with experienced operators, an emer-
gency conversion of CAS to CEA of 5% (EVA-3S), too many 
low volume centers, and incomplete antiplatelet drug therapy 
(EVA-3S). In addition, EPD was not mandatory in 27% in 
TABLE 1. Registries Reporting Outcome Data on CAS
Registry no. of Patients
Stroke/death/mI 
Rate (%)
ARCHER 2003 581 8.3
SECURITy 2003 383 8.5
BEACH 2004 480 5.8
MAVERIC 2004 498 5.3
CABERNET 2004 454 3.8
CREATE 2005 543 6.2
EMPIRE 2008 245 3.7
EPIC 2008 237 3
PROTECT 2008 274 1.8
ARMOUR 2009 263 2.7
CAS = carotid angioplasty & stenting; MI = myocardial infarction.
fIguRE 1. Device approval trials.
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SPACE and in 72% in ICSS; there was inaccurate analysis 
whereby MI was not considered as an endpoint (EVA-3S, 
SPACE) which is in favor of CEA, and; there was inappropri-
ate patient selection. A major issue relates to inexperienced 
operators. For example, in order to be enrolled in EVA-3S 
study, the operator had to justify 12 carotid procedures or at 
least five CAS plus 30 or more supraaortic trunk procedures. 
For SPACE study, 25 successful CAS procedures or assistance 
from a tutor with at least 10 carotid stents were considered 
adequate and for ICSS to be designated an “experienced” 
operator the criterion was the performance of 10 carotid 
stents among 50 endovascular stents. We know that training 
and experience as we will discuss later are very important to 
limit the complication rate of CAS. Such lack of experience 
of investigators performing CAS in these trials can only have 
tended to put CAS patients at increased risk of complications. 
Finally, none of these studies fulfills the criteria of good medi-
cal practice. 
3 .  C R E S T  S T u d y 1 5
The most recent published study, the CREST study, is the 
most important one. It is a prospective multicenter randomized 
controlled trial comparing CEA and CAS in 2502 patients; 
1326 symptomatic patients with a carotid artery stenosis 
≥50%, and 1196 asymptomatic patients with a stenosis ≥60%. 
Surgeons and interventionists were highly qualified. The de-
vices used were the Acculink carotid stent and Accunet EPD 
(Abbott Laboratories, Abbott Park, IL, USA). All patients 
also received the best medical management. To compare the 
safety and efficacy of the two treatments, the primary endpoints 
studied were any periprocedural stroke/death/myocardial in-
farction (MI) and any postprocedural ipsilateral stroke at up 
to 4 years of follow up. Cardiologists performed 42% of the 
CAS procedures, vascular surgeons 22%, radiologists 16%, 
neuroradiologists 12% and neurosurgeons 8%.
CAS and CEA appeared similar with regard to the study’s 
endpoint (stroke/death/MI) in symptomatic and asymptomatic 
patients (Fig. 2). At 30 days, the death/stroke/MI rate was 5.8% 
for CAS (N = 1131) and 5.1% for CEA (N = 1176) whithout 
any statistically significant difference (P = 0.52). However, 
the rate for any stroke was higher in the CAS group: 4.1% vs 
1.9% (P = 0.0019) but with higher rate of minor strokes of 
3.2% vs 1.5% (P = 0.0088). There was no difference for major 
stroke: CAS 0.9%, CEA 0.4% (P = 0.2005). The rate for MI 
was higher in the CEA group: 3.4% vs 2% (P = 0.0387).
It is important to point out that the excess risk of stroke 
in CAS was mainly due to minor stroke, and this is significant 
because any disability related to minor stroke typically goes 
away within 7 days and at 6 months the Neurological Residual 
Deficit Rates by NIHSS associated with minor strokes are 
equivalent (0.62% for CAS, 0.60% for CEA). Heart attacks, 
on the other hand, carry a late consequence that strokes 
do not, increasing the risk of dying in 2 to 3 years by about 
4-fold. When we compare the long-term mortality at 4 years, 
the freedom from all-cause mortality is 94.8% after minor 
stroke, 75% after MI (P = 0.02). Moreover, patients who had 
MI reported a better quality of life after recovery than those 
who had a stroke.
Concerning the long-term results, in a combination of 
symptomatic and asymptomatic patients, there are no differ-
ences in outcome for CAS and CEA (Fig. 3). At 4 years we 
observed a similar freedom from ipsilateral stroke of 96.7% for 
CEA and 96.5% for CAS (P = 0.89). The rates of ipsilateral 
stroke during a mean follow up of 2.5 years were equal at 2% 
for stenting and 2.4% for CEA (P = 0.51). We also observed a 
similar mortality at 4 years. The freedom from all-cause mor-
tality was 89.2% for CEA and 87.9% for CAS (P = 0.23). We 
also have to mention the problem of cranial nerve injury, never 
observed after CAS but reported in 5.3% of CEA patients (P 
= 0.001), unresolved at one month in 3.6% and at 6 months 
in 2.1%. The access site complication rate is also higher after 
CEA, 3.7% vs 1.1%, respectively (P = 0.0001).
Considering the age of the patient, CAS gave better re-
sults than CEA in young patients, CEA gave better results in 
elderly patients (Fig. 4). However, a subanalysis of CREST 
showed that although older patients have worse outcomes, 
the increase in complications is similar for CAS and CEA. In 
TABLE 2. European Studies: 30-Day Outcomes
CAS CEA P value
EvA-3S 10% 4% 0.01
SPACE 7% 6% NS
ICSS 8.5% 5.2% 0.006
CAS = carotid angioplasty & stenting; CEA = carotid endarterectomy; 
NS = non-significant
fIguRE 2. Crest study. Periprocedural endpoint components.
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octogenarians the complication rate is 11.6 % after CAS (N 
= 106) and 10.8% after CEA (N = 103), which is not statisti-
cally significant. Thus, octogenarians do not appear to be a 
contraindication for CAS.16 We have to point out that in the 
CREST study only a single first generation of stent and EPD 
was utilized and if we consider large recent published series 
reported in high volume centers with experienced operators, 
fIguRE 3. Crest study long term outcomes. fIguRE 4. Crest study results depending on age.
fIguRE 5. C.A.S. in octogenarians 30 day outcomes.
proper indications, choice of the techniques (stents, EPD, ap-
proach, etc.), CAS seems as safe as surgery in elderly patients. 
In the EMPIRE study, the 30-day death/stroke/MI rate was 
2.6% in octogenarians and in the ARMOUR study 3.1%. In 
our own series, the 30-day outcomes are similar in patients 
>80 years and in patients <80 years (Fig. 5).
What is also remarkable is the restenosis rate. CREST 
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showed that after 2 years of follow up, restenosis is infrequent 
and similar whether patients underwent CAS or CEA. The 
rate of restenosis and occlusion was 6% after CAS and 6.3% 
after CEA, not statistically different. Women and patients with 
diabetes or dyslipidemia had higher rates of stenosis, almost 
doubling the risk. Interestingly, smoking increased restenosis in 
CEA patients but appeared protective in the stenting group.17
R E g I S T R I E S  A n d  R A n d o m I z E d 
S T u d I E S :  I m P L I C A T I o n  
f o R  C L I n I C A L  P R A C T I C E 
Considering the latest registries and the CREST Study, 
CAS and CEA are equivalent. These 2 methods of carotid 
revascularization are safe and efficient for stroke prevention in 
carotid bifurcation disease. Physicians and patients now have 
the choice between CEA and CAS. Despite the difference in 
perioperative stroke prevention at up to 4 years of follow up, 
CREST lends justifiable support to physicians who choose 
to treat symptomatic and asymptomatic patients with carotid 
artery disease by stenting.18
CREST reported excellent clinical results for both stenting 
and surgery with low complication rates. Stenting seems to 
have similar results with endarterectomy in both symptomatic 
and asymptomatic patients. Considering the age of the patient 
at approximately age 69 and younger, stenting results are 
slightly better with a larger benefit for stenting the younger the 
age of the patient. For patients older than 70, surgical results 
are slightly superior to stenting with larger benefits for surgery 
the older the age of the patient. However, as we have previously 
discussed, with experienced operators in high volume centers 
and choice of devices, CAS seems at least not inferior to CEA 
and can be proposed to elderly patients and octogenarians.
Up to 2010, in the USA, CAS was only indicated for 
patients at high surgical risk. However, in May 2011, FDA 
approved expanded use of CAS wwithy the Acculink stenting 
system to patients at standard risk for adverse events from 
carotid surgery. The current accepted indications for FDA are 
symptomatic patients with a stenosis ≥50% or asymptomatic 
patients with a stenosis ≥60% by angiography. This large popu-
lation represents about two thirds of all carotid patients. All 
CAS candidates must have a reference vessel diameter between 
4 and 9 mm at the target lesion. The expanded indications are 
specifically for the Acculink carotid stent used in conjunction 
with the Rx Accunet EPD. This means that the use of any other 
EPD in standard risk patient would be off-label. However, 
there is no evidence of differences in outcomes between the 
various stents and EPDs.
There are limitations for CEA but also for CAS. We can 
not stent everyone. Clinicians should use the two therapies, 
CAS and CEA, in a complementary way so that patients get 
the lowest risk procedure possible. There will always be some 
patients who will do better with stenting and some who will 
do better with surgery. That is the way to reduce stroke rates 
and confer long-term benefit. We will discuss later the lesions 
to avoid or to treat with caution. Some lesions should be only 
treated by very experienced operators. If not, surgery could be 
the best option but as with CAS, CEA must also be performed 
by well trained surgeons and not by beginners.
H o W  T o  A v o I d  A n d  R E d u C E  
T H E  C o m P L I C A T I o n S  A S S o C I A T E d 
W I T H  C A S 1 9 , 2 0
1 .  A P P R o P R I A T E  I n d I C A T I o n S .  PA T I E n T  
A n d  L E S I o n  S E L E C T I o n
Before determining the indication for carotid revascu-
larization, a procedure assessment with several examinations 
and tests is indispensable whether the patient is symptomatic 
or asymptomatic and to recognize the high-risk patients for 
CAS or CEA. New parameters have been recently reported to 
define better indications particularly in asymptomatic patients. 
These examinations include clinical, biological and neurologi-
cal assessment, ultrasonic plaque morphology examination, 
transcranial Doppler (TCD), computed tomography (CT) scan 
and/or magnetic resonance imaging (MRI), diffusion-weighted 
(DW) MRI, angiographic evaluation, positron emission to-
mography (PET) and SPECT imaging in some patients, and 
finally criteria of plaque vulnerability.
1.1. Medical and cardiological assessment
Age is often listed as a high-risk factor, but it is the ana-
tomic challenges and medical co-morbidities that come with 
age that increase the risk for most patients. A cardiological 
examination is mandatory to recognize patients with severe 
coronary artery disease (left main stenosis, triple vessel dis-
ease), unstable angina, heart failure, recent MI, patients in 
need of urgent open heart or vascular surgery, patients with 
other cardiac, vascular or rhythm abnormalities, or uncon-
trolled high blood pressure.
A sudden decline in blood pressure and the onset of severe 
bradycardia during the procedure present major risk for MI 
and stroke. A careful monitoring of the blood pressure and 
of the heart rate during the procedure is indispensable to 
minimize the risk of MI or neurological complications (hyper-
tension syndrome, brain hemorrhage, stroke). The presence 
of severe peripheral vascular disease could favor brachial or 
radial access even direct carotid puncture to minimize access 
site difficulties and complications.
1.2. Neurological assessment
The neurological risk increases with recent large infarction 
with risk of brain hemorrhage. It is probably preferable to wait 
for six weeks before intervention in these circumstances, al-
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though there is little robust evidence to guide the intervention-
ist. However, newer data over the last 5-7 years have shown that 
CAS for symptomatic patients with neurological stabilization 
can be done in a much shorter time window.21 Other situations 
of increased neurological risk comprise crescendo transient 
ischemic attack (TIA), stroke in evolution, and elderly patients 
due to the lack of vascular reserve.
1.3. Biological assessment
Elderly diabetic patients could be at higher risk for CAS.22 
Also patients with chronic renal insufficiency have a higher 
risk of neurological complications.23
1.4. Echographic plaque characteristics
A good echographic evaluation is mandatory to recognize 
echolucent plaques which are at higher risk of embolization 
during CAS.24
1.5. Transcranial Doppler (TCD)
Spence et al25 reported that asymptomatic patients who 
have microemboli at baseline detected by TCD are more likely 
to have a stroke during the first year of follow up (15.6% vs 1%) 
and could benefit from revascularization. This technique may 
allow for better identification of a particular high-risk group of 
patients with carotid stenosis and particularity asymptomatic 
patients.
1.6. CT scan – MRI
Silent infarct is an independent risk factor for future 
stroke.26 Thus, the detection of silent brain infarcts on DW 
MRI or CT scan could reinforce the indications of CAS 
or CEA especially in asymptomatic patients. Patients with 
contralateral ischemic symptoms seem also at higher risk for 
neurological complications.
1.7. Angiographic evaluation
An angiography of the aortic arch, all supra-aortic vessels 
and of the intracranial arteries is indispensable before a CAS 
procedure. Some anatomical situations may lead to difficul-
ties to safely perform CAS, due to access problems, increasing 
the risk of the procedure. CEA could be better in some cases 
like complex bifurcation disease with long, multifocal lesions, 
very angulated internal carotid artery (ICA), extensive aortic 
or brachiocephalic trunk plaque, severe tortuosities, severe 
calcifications of the aorta and arch vessel, severe ulceration, 
heavy circumferential calcifications of the carotid bifurcation.
A good knowledge of the vessel anatomy is mandatory 
in order to decide on the appropriate approach or the best 
technique to use. A type 3 aortic arch could be challenging, 
particularly in elderly patients with very atheromatous arch. 
The aortic arch has its own set of embolic potential and is 
a substancial source of emboli. We have to avoid excessive 
catheter manipulation in this type of arch, which could detach 
atheromatous plaques and lead to showers of emboli to the 
brain. Distal loops, bends, kinks may be a contraindication 
to some protection devices. If a clot is suspected, CAS is 
contraindicated if the interventionist cannot use a proximal 
protection device.
1.8. Criteria of plaque vulnerability
Baseline C-reactive protein (CRP) was found to be a pow-
erful predictor of outcome in patients undergoing CAS. An 
elevated CRP value before CAS remained a significant and 
independent predictor of stroke and death within 30 days after 
CAS.27 Similarly an increased preprocedural leukocyte count 
independently predicted more frequent embolic events during 
CAS.28 In the future, virtual histology intravascular ultrasound 
imaging will perhaps identify vulnerable plaque with embolic 
potential in patients undergoing CAS.29
2 .  C o R R E C T  T E C H n I q u E  o f  C A S
We have to select the best procedural approach depend-
ing on the anatomy. Most of the time we use the femoral 
approach but in some patients (tortuous arteries, difficult 
aortic arch, type III aortic arch, bovine arch, etc.) a brachial 
or radial approach, even a direct puncture of the common 
carotid artery are the best options to minimize the neurologi-
cal complications.
3 .  E m B o L I C  P R o T E C T I o n  d E v I C E S 1 9 , 2 0 , 3 0
Embolic protection devices (EPD) should be used in any 
CAS procedure. We have the choice among 3 techniques: 
distal occlusion with balloon occlusion, filters, and proximal 
protection devices (gore Neuroprotection System, W. L. gore 
& Associates, Inc., Flagstaff, AZ, USA; or Moma device, 
Invatec, Medtronic, Bethlehem, PA, USA).
According to the metaanalysis of garg et al (134 reports),31 
EPD reduced the risk of perioperative stroke with CAS. A 
total of 12263 protected CAS procedures were compared with 
11198 unprotected CAS procedures. The relative risk (RR) 
for stroke was 0.62 (95% CI: 0.54 to 0.72) in favor of protected 
CAS. In the CREST study, 24 patients were treated without 
EPD with a 30-day death, stroke, MI rate of 20.8% compared 
to 5.3% for patients treated with EPD.
Choosing EPD is crucial and depends on the interven-
tionist, the lesion, the anatomy of the different vessels, the 
intracranial circulation and the collateral circulation. An oc-
clusion balloon or flow reversal system are contraindicated in 
cases of poor collateral circulation and contralateral occlusion. 
Patients presenting with tortuous supraaortic vessels or type 3 
aortic arch require a low profile flexible EPD. Flow reversal 
systems seem inadequate due to their larger profile, but may be 
beneficial in cases with very tortuous ICA, severely angulated 
ICA kinks, bends above the carotid stenosis or if thrombi are 
suspected. Some authors advise proximal occlusion to treat 
plaques with very high risk of brain embolization (soft plaques, 
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dyshomogenous, plaques, plaques with gray-scale median 
(gSM) <25). However, a very low profile filter can be useful 
to treat lesions in tortuous vessels. New low profile filters with 
their retrieval catheter which is an aspiration catheter like the 
FiberNet Filter (Medtronic Inc, Santa Rosa, CA, USA) seem 
promising to treat high risk plaques.32 
A question arises whether all protection devices are equiva-
lent in humans. Iyer et al33 reported a multicenter study analyz-
ing 3160 CAS procedures using 9 different types of EPD. There 
was no significant difference in the risk of procedural adverse 
events for any EPD. In the EMPIRE and ARMOUR studies 
with proximal protection devices, the 30-day death/stroke/MI 
rates were respectively 3.7% and 2.7%, not different from any 
other EPD. However, we have to mention that with proximal 
protection it seems that we observe less microemboli and less 
new cerebral ischemic lesions on DW-MRI.34
4 .  C H o I C E  o f  T H E  S T E n T  
A n d  C o R R E C T  I m P L A n T A T I o n
Two types of stents can be selected for the carotid bifur-
cation: closed cell stent design, either the Wallstent (Boston 
Scientific, Natick, MA, USA) or nitinol stents (Xact stent, 
Abbott, IL, USA; NexStent, Boston Scentific, MN, USA), and 
open cell stent design, such as the Precise (Cordis, NJ, USA), 
Acculink (Abbott, IL, USA), Protege (ev3, MN, USA), or 
Exponent (Medtronic Vascular Inc., CA, USA) stents.
Bosier et al35 reported a higher neurological complication 
rate after implantation of open cell than closed cell stents 
(11.1% vs 3%). It is also now well demonstrated that the ma-
jority of strokes occur post procedure and before discharge. 
Furthermore, it seems that the free cell area influences the 
outcome in CAS. In Bosier’s report the post procedural 
rate analysed for different stents varied from 1.2% using a 
closed cell stent (Wallstent) to 5.9% using an open cell stent 
(Medtronic Exponent). The late events varied from 1.2% to 
3.4% for free cell area <2.5 mm² and 7.5 mm² respectively 
(P<0.05). Post procedural event rate was 1.3% for closed 
cells and 3.4% for open cells. All these differences were highly 
pronounced among symptomatic patients (p<0.001). 
In the SPACE study,13 the same influence of stent cell 
design was reported. The neurological complication rate was 
5.9% with closed cell stents and 11% with open cell stents. 
Schillinger et al36 reported a registry of 1684 patients with 
results which conflict with those of Bosier’s et al. Combined 
TIA, stroke or death rates and stroke or death within 30 days 
of treatment were 6.1% (95% CI, 5.0 to 7.2) and 3.1% (95% 
CI, 2.3 to 3.9) for the closed cell design versus 4.1% (95% 
CI, 3.2 to 5.0) and 2.4% (95% CI, 1.7 to 3.1) for the open-
cell design stents (P=0.077, P=0.38), respectively, without 
significant differences in asymptomatic and symptomatic 
patients. These data do not support the superiority of specific 
carotid stent cell design with respect to neurologic complica-
tions stroke and mortality risk. However, if we analyse more 
carefully these data, we can see that the event rate at day 1 
through day 30 in symptomatic patients is 0.3% with closed 
cell and 1.39 with open-cell stents (P=0.03). Thus, open cell 
stents could give a better protection against delayed embolic 
events in symptomatic patients. Hornung37 reported a series 
of 845 CAS procedures and found that the acute and subacute 
results of CAS were not significantly different between open 
and closed cell stents. There was a trend towards better results 
with open cell stents in symptomatic patients. Despite these 
different opinions, we recommend to use closed cell design 
stents except in tortuous vessels where open cell stents are 
more appropriate. In that case we advise to use open cell 
stents with the smallest free cell area. Regarding the size of 
the stent, the diameter is chosen depending on the diameter 
of the common carotid artery and the length depending on 
the length of the lesion.
5 .  P H A R m A C o L o g I C A L  A d j u n C T S 
Platelet antiaggregants are mandatory (aspirin, clopidog-
rel, etc) and it is also most important to control blood pressure 
and heart rate during and after the procedure.
6 .  L E A R n I n g  C u R v E .  
E x P E R I E n C E d  o P E R A T o R S
Increase in operator experience coupled with improve-
ments in techniques and patient selection likely contributed to 
marked improvements in CAS outcomes as recently reported 
by W. gray in 4 studies in high risk patients (Fig. 6) and in the 
CREST study (Fig. 7). In this latter study, the learning curve 
and experience played a major role and in particular in elderly 
patients and octogenarians. In the period between 2000-2004, 
death and major stroke rate was 6.5% and between 2006-2008 
0% (Fig. 8). Lin et al39 reported clearly that the complication 
rate is dramatically reduced with experience. In their series, 
the complication rate was 18% for the first 50 patients, 8% 
for the group of patients between number 51 and 100, and 
2% after the first 100 procedures. It is well known that the 
poor results published in the EVA3S (88) and SPACE (98) 
studies are for a large part due to inexperienced operators. All 
these data demonstrate that CAS is a challenging procedure 
which should the performed by experienced operators, in high 
volume centers with a proper choice of different techniques 
(EPD, stents, etc.).
C o n C L u S I o n
The CREST study and recently published data have shown 
that CAS and CEA are equivalent for the treatment of a 
carotid stenosis. However, these two treatments have respec-
tive contraindications and limitations. For each intervention, 
there is a need for appropriate patient and lesion selection, 
good technique, embolic protection devices and experienced 
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fIguRE 6. C.A.S. under protection 4 studies in high risk pa-
tients.
fIguRE 7. Crest study outcomes overtime.
fIguRE 7. C.A.S. Crest study - Εlderly patients.
operators. Indications for asymptomatic patients have to be 
discussed considering the benefit of optimal medical therapy 
and need a large number of new parameters (Duplex scan, 
plaque histology, brain perfusion imaging, etc.).
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